Due to typographical error, the company inadvertently mentioned wrong numbers in few lines of financial results as mentioned in Annexure I. Please note that there is no change in the broader ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Eiko Lifesciences has revised its audited standalone and consolidated results for Q4 and FY ended 31 March 2025 to correct typographical errors in a few line items; broader financial heads remain unchanged. On a standalone basis, revenue from operations rose ~16% to Rs 3,249 lakhs (vs Rs 2,793 lakhs in FY24) and profit after tax jumped ~131% to Rs 174 lakhs (vs Rs 75 lakhs). Consolidated revenue stood at Rs 3,766 lakhs with PAT of Rs 232 lakhs and EPS of Rs 1.62. An exceptional item of Rs 34.12 lakhs reflects interest received from shareholders on delayed payment of the First and Final Call money on Rights Equity Shares. Statutory auditor PSV Jain & Associates issued an unmodified opinion. The board also appointed M/s Shravan Gupta & Associates as Secretarial Auditor (5 years) and M/s NP Rajput & Co as Internal Auditor for FY26.
The revision is purely cosmetic and reassures investors that the underlying numbers are unchanged; however, a chunk of the sharp PAT growth comes from a one-off exceptional interest receipt, which may not recur.